BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 24764162)

  • 41. Humoral anti-OV-TL 3 response after the intravenous administration of radiolabelled Fab' or F(ab')2 fragments in ovarian cancer patients.
    Tibben JG; Thomas CM; Massuger LF; Segers MF; Schijf CP; Corstens FH; Boerman OC
    Nucl Med Commun; 1995 Oct; 16(10):853-9. PubMed ID: 8570116
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
    Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
    J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
    Vallabhajosula S; Smith-Jones PM; Navarro V; Goldsmith SJ; Bander NH
    Prostate; 2004 Feb; 58(2):145-55. PubMed ID: 14716739
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biodistribution of radiolabeled monoclonal antibody E48 IgG and F(ab')2 in patients with head and neck cancer.
    de Bree R; Roos JC; Quak JJ; den Hollander W; Wilhelm AJ; van Lingen A; Snow GB; Dongen GA
    Clin Cancer Res; 1995 Mar; 1(3):277-86. PubMed ID: 9815983
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
    Yokota T; Milenic DE; Whitlow M; Wood JF; Hubert SL; Schlom J
    Cancer Res; 1993 Aug; 53(16):3776-83. PubMed ID: 8339291
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F(ab')2, and Fab' conjugated to Pseudomonas exotoxin.
    Siegall CB; Gawlak SL; Chin JJ; Zoeckler ME; Kadow KF; Brown JP; Braslawsky GR
    Bioconjug Chem; 1992; 3(4):302-7. PubMed ID: 1390985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.
    Sham JG; Kievit FM; Grierson JR; Chiarelli PA; Miyaoka RS; Zhang M; Yeung RS; Minoshima S; Park JO
    J Nucl Med; 2014 Dec; 55(12):2032-7. PubMed ID: 25359880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
    Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
    Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
    DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
    Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts.
    Colapinto EV; Humphrey PA; Zalutsky MR; Groothuis DR; Friedman HS; de Tribolet N; Carrel S; Bigner DD
    Cancer Res; 1988 Oct; 48(20):5701-7. PubMed ID: 3167830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
    Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
    Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Labeling monoclonal antibodies and F(ab')2 fragments with (111In) indium using cyclic DTPA anhydride and their in vivo behavior in mice bearing human tumor xenografts.
    Powe J; Pak KY; Paik CH; Steplewski Z; Ebbert MA; Herlyn D; Ernst C; Alavi A; Eckelman WC; Reba RC
    Cancer Drug Deliv; 1984; 1(2):125-35. PubMed ID: 6544629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of radiolabeled stabilized F(ab')2 fragments of monoclonal antiferritin in nude mouse model.
    Quadri SM; Lai J; Mohammadpour H; Vriesendorp HM; Williams JR
    J Nucl Med; 1993 Dec; 34(12):2152-9. PubMed ID: 8254403
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biodistribution in normal mice of an 111In-labelled prostatic acid phosphatase-specific antibody and its F(ab')2 fragments derivatized site-specifically or via bicyclic diethylenetriaminepentaacetic acid anhydride.
    Perälä M; Vihko P; Södervall M; Heikkilä J; Vihko R
    Eur J Nucl Med; 1990; 16(8-10):621-6. PubMed ID: 2384100
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancing Treatment Efficacy of
    Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
    Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.
    Colapinto EV; Zalutsky MR; Archer GE; Noska MA; Friedman HS; Carrel S; Bigner DD
    Cancer Res; 1990 Mar; 50(6):1822-7. PubMed ID: 2407345
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments.
    Schott ME; Frazier KA; Pollock DK; Verbanac KM
    Bioconjug Chem; 1993; 4(2):153-65. PubMed ID: 7873647
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody.
    Khawli LA; Alauddin MM; Hu P; Epstein AL
    Cancer Biother Radiopharm; 2003 Dec; 18(6):931-40. PubMed ID: 14969605
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy.
    Behr TM; Memtsoudis S; Sharkey RM; Blumenthal RD; Dunn RM; Gratz S; Wieland E; Nebendahl K; Schmidberger H; Goldenberg DM; Becker W
    Int J Cancer; 1998 Aug; 77(5):787-95. PubMed ID: 9688314
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody.
    Carter T; Sterling-Levis K; Ow K; Doughty L; Hattarki M; Shapira D; Hewish D; Kortt AA; Russell PJ
    Cancer Immunol Immunother; 2004 Jun; 53(6):533-42. PubMed ID: 14722669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.